In fact, the randomized phase 3 PACIFIC trial established a new standard for unresectable LA-NSCLC, introducing the concept of immunotherapy maintenance with the anti-programmed-death ligand 1 (anti-PD-L1) agent Durvalumab, for patients without progressive disease after CRT. The gene discussed is CD274; the disease is non-small cell lung carcinoma.